Tech Company Financing Transactions
Orphagen Pharmaceuticals Funding Round
Small Business Innovation Research (SBIR) invested in a $1.7 million funding round for Orphagen Pharmaceuticals. The round closed on 12/9/2024.
Transaction Overview
Company Name
Announced On
12/9/2024
Transaction Type
Venture Equity
Amount
$1,700,000
Round
Undisclosed
Proceeds Purpose
The funding will support the preclinical development of the small molecule OR-812, a selective nuclear receptor antagonist, as a novel oral therapeutic for treatment of ulcerative colitis and Crohn's disease, two forms of inflammatory bowel disease (IBD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11558 Sorrento Valley Road 4
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
At Orphagen, we are pioneering targeted therapies to tackle cancer and other serious diseases. With breakthroughs emerging from our internal discovery engine, we are developing a portfolio of small-molecule therapeutics that aim precisely at "orphan" or yet-to-be-explored members of the highly successful nuclear receptor drug target superfamily.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Thacher
Vice President
Paul Crowe
Browse more venture capital transactions:
Prev: 12/9/2024: Prezent.ai venture capital transaction
Next: 12/9/2024: Clinikk venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs